The results of this study suggest that drug sensitivity to eribulin and capecitabine may vary based on HER2 expression among patients with HER2-low and HER2-null breast cancers; however, there was no difference in prognosis between the two groups. The gene discussed is ERBB2; the disease is breast carcinoma.